Orthotopic Pancreatic Cancer Model

on this page

Results

Results

Orthotopic Pancreatic Cancer Model: B-luc MIA PaCa-2 in B-NDG Mice

Establishment of orthotopic pancreatic cancer model

Establishment of orthotopic pancreatic cancer model.
The B-NDG mice (F, n=5) were inoculated with B-luc MIA PaCa-2 cell suspension (1×10⁵, 2×10⁵), which were mixed with Matrigel (1:1), and the body weight and tumor fluorescence signal of the mice were recorded weekly. The results showed that the fluorescence signal gradually increased, and the body weight of mice gradually decreased slightly in the later stage. This indicates that the cell line was successfully constructed as an orthotopic tumor model. H&E staining showed that tumors metastasized in the kidney and liver.

Orthotopic pancreatic cancer models imaging by Micro-CT

Orthotopic pancreatic cancer models imaging by Micro-CT.
A: Micro-CT images of B-Luc MIA PaCa-2 orthotopic model in B-NDG mice were scanned from day 14 after inoculation. The image shows the coronal planes of the mice abdomen, with red region representing the actual tumor. B: Tumor growth curves were recorded by contrast-enhanced CT. C: Dynamic changes of fluorescence signal in the tumor site after inoculation.

Antitumor activity of Antibody-drug conjugate in B-luc MIA PaCa-2 pancreatic orthotopic model

Study ID:	Groups	Animal number	Treatment	Dosage (mg/kg)	Lot No.	Dosing Volume	Dosing Route	Treatment Schedule	Treatment Times
21P079513	G1	6	PBS	-	2425263	10μL/g	i.p.	QW	2
	G2	6	ADC	1mpk	-	10μL/g	i.p.	QW	2
	G3	6	ADC	3mpk	-	10μL/g	i.p.	QW	2

Antitumor activity of Antibody-drug Conjugate in B-luc MIA PaCa-2 Pancreatic orthotopic model. The ADC significantly inhibited B-luc MIA PaCa-2 tumor growth in B-NDG mice. B-luc MIA PaCa-2 cells (1×10⁵) suspension mixed in Matrigel solution (1:1) was orthotopically implanted into B-NDG mice (female, 7 week-old, n=6). Mice were grouped when Imaging signal value reached approximately 7×10⁷ p/sec, at which time they were treated with the ADC drug with different doses and schedules indicated in panel (A) Body weight changes during treatment. As shown in panel B, this ADC drug was efficacious but mild, demonstrating that B-luc MIA PaCa-2 Pancreatic orthotopic model could provide a powerful preclinical model for in vivo evaluation of ADC drug. Values are expressed as mean ± SEM. *p<0.05.

Study ID:	Groups	Animal number	Treatment	Dosage (mg/kg)	Lot No.	Dosing Volume	Dosing Route	Treatment Schedule	Treatment Times
24P071530	G1	6	PBS	-	2933643	10μL/g	i.v.	QW	2
	G2	6	DS-8201	3mpk	394042	10μL/g	i.v.	QW	2
	G3	6	DS-8201	6mpk	394042	10μL/g	i.v.	QW	2

Antitumor activity of anti-HER2 antibody in B-luc MIA PaCa-2 Pancreatic orthotopic model. The DS-8201 significantly inhibited B-luc MIA PaCa-2 tumor growth in B-NDG mice. B-luc MIA PaCa-2 cells (1×10⁵) suspension mixed in Matrigel solution (1:1) was orthotopically implanted into B-NDG mice (female, 7 week-old, n=6). Mice were grouped when Imaging signal value reached approximately 7×10⁷ p/sec, at which time they were treated with the DS-8201 with different doses and schedules indicated in panel (A) Body weight during treatment. As shown in panel B, this drug was efficacious but mild, demonstrating that B-luc MIA PaCa-2 Pancreatic orthotopic model could provide a powerful preclinical model for in vivo evaluation of DS-8201. Values are expressed as mean ± SEM. *p<0.05, ***p<0.001, ****p<0.0001.

Orthotopic Pancreatic Cancer Model: B-CMV-Luc Panc 02.03#mix + B-NDG mice (orthotopic)

Study ID:	Groups	Animal strain	Sex	Cell line	The amount of cells Inoculated	The Volume of cells	Animal number	Remarks
24P071545	G1	B-NDG mice	F	B-CMV-Luc Panc 02.03#mix	5×10⁵	0.04ml/mice	6	Orthotopic
	G2	B-NDG mice	F	B-CMV-Luc Panc 02.03#mix	1×10⁶	0.04ml/mice	6	Orthotopic
	G3	B-NDG mice	F	B-CMV-Luc Panc 02.03#mix	2×10⁶	0.1ml/mice	6	Subcutaneously on the right flank

B-CMV-Luc Panc 02.03#mix + B-NDG mice (orthotopic) img

Establishment of orthotopic pancreatic cancer model.
The B-NDG mice (F, n=6) were inoculated with B-CMV-Luc Panc 02.03#mix suspension (5×10⁵, 1×10⁶, 2×10⁶) at the head of the pancreas or subcutaneously on the right flank. And the body weight and tumor fluorescence signal of the mice were recorded weekly. The results showed that the fluorescence signal gradually increased. This indicates that the cell line was successfully constructed as an orthotopic tumor model.

Orthotopic Pancreatic Cancer Model: B-Tg(CMV-Luc-EGFP) PANC-1#1-G02 + B-NDG mice (orthotopic)

Study ID:	Groups	Animal strain	Sex	Cell line	The amount of cells Inoculated	The Volume of cells	Animal number	Remarks
24P071546	G1	B-NDG mice	F	B-Tg(CMV-Luc-EGFP) PANC-1#1-G02	5×10⁵	0.04ml/mice	6	Orthotopic
24P071546	G2	B-NDG mice	F	B-Tg(CMV-Luc-EGFP) PANC-1#1-G02	1×10⁶	0.04ml/mice	6	Orthotopic

B-Tg(CMV-Luc-EGFP) PANC-1#1-G02 + B-NDG mice (orthotopic) img

Establishment of orthotopic pancreatic cancer model.
The B-NDG mice (F, n=6) were inoculated with B-Tg(CMV-Luc-EGFP) PANC-1#1-G02 suspension (5×10⁵, 1×10⁶) at the head of the pancreas. And the body weight and tumor fluorescence signal of the mice were recorded weekly. The results showed that the fluorescence signal gradually increased. This indicates that the cell line was successfully constructed as an orthotopic tumor model.

Orthotopic Pancreatic Cancer Model

Publication

Results